SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
119.57
-3.64 (-2.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close123.21
Open123.00
Bid118.58 x 1100
Ask119.60 x 800
Day's Range118.91 - 123.78
52 Week Range95.21 - 176.50
Volume668,209
Avg. Volume1,011,325
Market Cap8.867B
Beta (3Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-5.93
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est203.71
Trade prices are not sourced from all markets
  • Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray
    American City Business Journals3 days ago

    Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray

    The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPTView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold SRPT had net inflows of $1.47 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here’s What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)
    Insider Monkey6 days ago

    Here’s What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)

    Is Sarepta Therapeutics Inc (NASDAQ:SRPT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]

  • Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
    Motley Fool7 days ago

    Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

    Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.

  • Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue?
    Zacks9 days ago

    Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue?

    Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Vertex Expands Collaboration With CRISPR, Acquires Exonics
    Zacks9 days ago

    Vertex Expands Collaboration With CRISPR, Acquires Exonics

    Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.

  • Vertex enters Duchenne field with $245M buy of Exonics
    American City Business Journals10 days ago

    Vertex enters Duchenne field with $245M buy of Exonics

    Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.

  • GlobeNewswire12 days ago

    Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., June 04, 2019 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management.

  • GlobeNewswire16 days ago

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to thirty-two individuals hired by Sarepta in May 2019. The employees received, in the aggregate, options to purchase 62,720 shares of Sarepta's common stock, and in the aggregate, 31,400 restricted stock units (“RSUs”). The options have an exercise price of $ 113.85 per share, which is equal to the closing price of Sarepta's common stock on May 31, 2019 (the “Grant Date”).

  • Market Weekly Review: Lower Prices Create Buying Opportunities
    TipRanks21 days ago

    Market Weekly Review: Lower Prices Create Buying Opportunities

    Despite gains for U.S. stocks on Friday, the Dow Jones Industrial Average ended lower for a fifth straight week—which is the longest streak since 2011.After a white-hot start to 2019, it’s been a wild wide for investors in the month of May. As the war of words has progressed in the trade battle between China and the U.S., price volatility has been on the increase. Use Volatility to Your AdvantageInvestors tend to shy away from volatility, which is a word that generally is only mentioned when prices are moving lower. In fact, the CBOE Volatility Index (VIX) is often referred to as the “fear gauge.”However, seasoned investors realize that volatility can be your friend. By taking a contrarian stance and buying when prices are lower, you have an opportunity to enter positions at optimal prices and boost long-term performance.“When you put it all together, this is a healthy time to come into the market for the long term,” said Thorne Perkin, president of Papamarkou Wellner Asset Management told CNBC on May 16. “We always look at these pullbacks as buying opportunities for the long term.” Short Holiday WeekThe U.S. markets will be closed next Monday for the Memorial Day holiday. In a short week, Costco (COST), Dell (DELL) and Gap (GPS) are all scheduled to report quarterly results next Thursday. On the economic front, we’ll also get a revision to the reading of first-quarter GDP growth next Thursday. The initial reading last month printed a solid 3.2%. As Memorial Day signals the unofficial start of Summer, look for trading volume to be relatively low next week. With a lot of professional investors at the beach, savvy market watchers will look to take advantage of the increased volatility that can accompany light trading volume. I know that’s the tack I will be taking with the Smart Investor portfolio next week and into the summer. Rather than shy away from any continued volatility, I’ll look to make more purchases, if the market continues to create buying opportunities.The fact remains that attractive investments are out there, if you’re willing to dig a little deeper.One such consumer name that’s worth a closer look is our Stock of the Week below… Stock of the Week: Sarepta Therapeutics (SRPT)Sarepta is a biopharmaceutical firm that’s in the business of treating rare neuromuscular diseases. The company currently has a treatment on the market for Duchenne muscular dystrophy (DMD), Exondys 51; but Sarepta is no one-trick pony. Management filed for approval of a second DMD treatment, golodirsen, in February.We recently added SRPT to our Smart Investor portfolio and are pleased to see that shares were flat compared with another down week for the broader markets. The stock has also gained 3% in the month of May, while the S&P 500 has lost nearly 4%.Looking ahead, these gains should keep on coming. Here’s why:DMD is a rare, but deadly genetic disease. The U.S. Food and Drug Administration has granted Sarepta priority review status to golodirsen and will receive an approval decision by Aug. 19, because of its potential impact. The company is not the only entrant in the DMD market, but management believes that it has at least a one-year head start on Pfizer’s (PFE) attempt to enter the arena. In total, Sarepta has a robust clinical pipeline with over 20 therapies, in various stages of research and development. Earlier this month, the company posted quarterly results that exceeded expectations. Sarepta lost $0.75 a share in the first quarter, while revenue increased 35% from the previous year, to $87 million.Yes, the company is losing money and consensus analyst estimates do not expect sustainable profitability until 2021. However, if Sarepta continues to deliver success in the clinical pipeline that day could come sooner and bring a considerably higher stock price along with it. Analysts See Higher Prices AheadIn the meantime, the analyst community is upbeat about the company’s future. 18 of 19 active analysts rate the stock a Buy (with 1 Hold) and the average price target of $202.13 suggests 67% upside potential.View SRPT Price Target & Analyst Ratings DetailAnalyst Alethia Young of Cantor Fitzgerald sums up the biopharma’s outlook here: “For Sarepta, the focus remains on continued pipeline advancement and growing gene therapy manufacturing capabilities. We continue to see many transformative updates for the company over the coming months, including a potential golodirsen approval on 8/19, potential casimersen approval in 1Q2020, and PPMO data around YE19/1Q20. Key trial initiations include commercial microdystrophin by YE19 and Charcot-Marie-Tooth in 2019.”Moreover, she adds: “We see significant revenue growth ahead with launches and also think the pipeline remains undervalued.” As a result, this top-ranked analyst reiterated her Buy rating with a bullish $231 price target on May 9. From current levels that suggests shares can surge 91%.Finally, I’m encouraged to note the stock sports a Smart Score of 10/10 on TipRanks, underlining the potential for continued price momentum. This new proprietary metric utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor of future outperformance. View SRPT Smart Score DetailIn addition to the catalysts mentioned above, Smart Score notes that Sarepta has positive sentiment from both hedge funds and investment bloggers.Looking for more top-rated stocks? Check out Analysts' Top Stocks here...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Sarepta Therapeutics Inc Earnings Call

  • This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
    Investor's Business Dailylast month

    This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note

    An analyst suggested investors look at Sarepta Therapeutics' array of gene therapies on Tuesday after rival Solid Biosciences reported its key gene therapy caused side effects in a patient.

  • Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript

    SRPT earnings call for the period ending March 31, 2019.

  • Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
    Zackslast month

    Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

    Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

  • When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
    Simply Wall St.last month

    When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 47.81% and 0.11%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Sarepta Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.07. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., May 08, 2019 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the.

  • ACCESSWIRElast month

    Sarepta Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...

  • GlobeNewswirelast month

    Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide Children’s) giving Sarepta the exclusive option to a Nationwide Children’s gene therapy candidate, calpain 3 (CAPN-3), to treat Limb-girdle muscular dystrophy type 2A (LGMD2A). LGMDs represent a group of distinct genetic neuromuscular diseases with a generally common set of symptoms, including progressive, debilitating weakness and wasting that begins in muscles around the hips and shoulders before progressing to muscles in the arms and legs.

  • Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
    GuruFocus.comlast month

    Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

    Fund releases 1st-quarter portfolio

  • GlobeNewswire2 months ago

    Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, May 8, 2019. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. Please specify to the operator that you would like to join the "Sarepta First Quarter 2019 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days.